Auricula Biosciences is a project-focused company currently developing a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. Ras mutation is the most frequent oncogenic alteration in human cancers and confers a poor prognosis as current targeted therapies are effective only in a minority of patients and hampered by the development of drug resistance. Auricula’s therapeutic candidate has been designed to bypass such resistance.
